British Oxfam Urges Thailand Not To Scrap Compulsory-Licensing Policy
This article was originally published in PharmAsia News
Oxfam, an England-based non-government organization, called on the new government in Thailand to maintain the compulsory-licensing policy of the previous government as a way to keep the prices of life-saving drugs affordable. The group's HIV/AIDS director expressed his concern based on the new government's decision to review the policy. The director said the actions of the previous military-led administration made key AIDS drugs, Bristol-Myers Squibb's Stocrin (efavirenx), sold in the United States as Sustiva, and Abbott Laboratories' version Kaletra (lopinavir, ritonavir), more accessible to more than 120,000 patients. (Click here for more
You may also be interested in...
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.